• Je něco špatně v tomto záznamu ?

An anti-hair loss treatment in the management of mild androgenetic alopecia: Results from a large, international observational study

P. Reygagne, VD. Mandel, C. Delva, M. Havlíčková, K. Padlewska, R. Khalil, V. Meuleman, GA. Miranda, M. Nevskaya, JF. Michelet, F. Pouradier, S. Vano-Galvan, D. Kerob

. 2021 ; 34 (6) : e15134. [pub] 20211022

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc22019640

Androgenic alopecia (AGA) is a common and chronic condition. It may impact self-esteem, self-image and quality of life. Benefit, tolerability, cosmetic acceptance and patient satisfaction are key to ensure good treatment outcome. Hair loss improvement and hair quality with AC5 (2,4-Diamino-Pyrimidine-N-Oxyde, arginine, 6-O glucose linoleate (SP94), piroctone olamine and Vichy mineralizing water) once daily was assessed in 527 subjects with mild AGA in an open-label, observational, international real-life study. After 3 months, investigators evaluated the impact of AC5 on hair loss, product satisfaction and asked subjects about local tolerance; subjects assessed hair growth and quality and satisfaction. Data from 357 subjects were evaluable for the benefit analysis; 59.9% of subjects were female; the mean age was 33.6±8.7 years. Duration of hair loss was 1.62±2.24 years. 71.3% of women had a Ludwig score of 1 and 40.8% of men had a Hamilton Norwood score of 2. At the end of study, hair loss was reduced in 89.0% of subjects; it was slightly higher in women (92.5%) than in men (83.8%). Subject satisfaction on a scale from 0 (not satisfied at all) to 10 (completely satisfied) was 7.9±1.7. Tolerance was rated good to very good by 98.6% of all subjects. In conclusion, AC5 reduces mild AGA in both men and women with a pleasant texture. AC5 was well tolerated and highly appreciated.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019640
003      
CZ-PrNML
005      
20220804135843.0
007      
ta
008      
220720s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1111/dth.15134 $2 doi
035    __
$a (PubMed)34532936
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Reygagne, Pascal $u Centre Sabouraud, Hôpital Saint-Louis, Paris, France
245    13
$a An anti-hair loss treatment in the management of mild androgenetic alopecia: Results from a large, international observational study / $c P. Reygagne, VD. Mandel, C. Delva, M. Havlíčková, K. Padlewska, R. Khalil, V. Meuleman, GA. Miranda, M. Nevskaya, JF. Michelet, F. Pouradier, S. Vano-Galvan, D. Kerob
520    9_
$a Androgenic alopecia (AGA) is a common and chronic condition. It may impact self-esteem, self-image and quality of life. Benefit, tolerability, cosmetic acceptance and patient satisfaction are key to ensure good treatment outcome. Hair loss improvement and hair quality with AC5 (2,4-Diamino-Pyrimidine-N-Oxyde, arginine, 6-O glucose linoleate (SP94), piroctone olamine and Vichy mineralizing water) once daily was assessed in 527 subjects with mild AGA in an open-label, observational, international real-life study. After 3 months, investigators evaluated the impact of AC5 on hair loss, product satisfaction and asked subjects about local tolerance; subjects assessed hair growth and quality and satisfaction. Data from 357 subjects were evaluable for the benefit analysis; 59.9% of subjects were female; the mean age was 33.6±8.7 years. Duration of hair loss was 1.62±2.24 years. 71.3% of women had a Ludwig score of 1 and 40.8% of men had a Hamilton Norwood score of 2. At the end of study, hair loss was reduced in 89.0% of subjects; it was slightly higher in women (92.5%) than in men (83.8%). Subject satisfaction on a scale from 0 (not satisfied at all) to 10 (completely satisfied) was 7.9±1.7. Tolerance was rated good to very good by 98.6% of all subjects. In conclusion, AC5 reduces mild AGA in both men and women with a pleasant texture. AC5 was well tolerated and highly appreciated.
650    _2
$a dospělí $7 D000328
650    12
$a alopecie $x farmakoterapie $x terapie $7 D000505
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a vlasy, chlupy $7 D006197
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a spokojenost pacientů $7 D017060
650    12
$a kvalita života $7 D011788
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Mandel, Victor Desmond $u Dermatology Unit, Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy $1 https://orcid.org/0000000306826148
700    1_
$a Delva, Catherine $u SyliaStat Lancrenon, Bourg-la-Reine, France
700    1_
$a Havlíčková, Michaela $u Poliklinika Chmelnice, Praha, Czech Republic
700    1_
$a Padlewska, Kamila $u ORICEA Esthetic Dermatology & Anti-Aging Medicine, Warszawa, Poland
700    1_
$a Khalil, Rose $u Dermatology Clinic, Dahr Sarba Jounieh, Sarba, Lebanon
700    1_
$a Meuleman, Veronique $u Private Practice, Tielt, Belgium
700    1_
$a Miranda, Gilberto Adame $u Del Valle Centro, Ciudad de México, CDMX, Mexico
700    1_
$a Nevskaya, Mariya $u Trichology and Cosmetology Center of Tatyana Tsimbalenko, Moscow, Russian Federation
700    1_
$a Michelet, Jean-Francois $u L'Oréal Research and Innovation, Aulnay-sous-Bois, France
700    1_
$a Pouradier, Florence $u L'Oréal Research and Innovation, Saint-Ouen, France
700    1_
$a Vano-Galvan, Sergio $u Trichology Unit. #TricoHRC Research Group, Department of Dermatology, Ramón y Cajal University Hospital, Madrid, Spain $1 https://orcid.org/0000000327737494
700    1_
$a Kerob, Delphine $u Laboratoires Vichy International, Levallois Perret, France
773    0_
$w MED00005384 $t Dermatologic therapy $x 1529-8019 $g Roč. 34, č. 6 (2021), s. e15134
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34532936 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135836 $b ABA008
999    __
$a ok $b bmc $g 1823018 $s 1170883
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 34 $c 6 $d e15134 $e 20211022 $i 1529-8019 $m Dermatologic therapy $n Dermatol Ther $x MED00005384
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace